Nav: Home

Long thought harmless, a glycan biomarker may cause pancreatic disease and cancer

June 20, 2019

A widely recognized biomarker for pancreatic disease, CA19-9, thought to be benign for decades, may in fact be a promoter for the development of these diseases, including pancreatic cancer. The unexpected results were revealed using genetically engineered mice and organoid models of pancreatic disease and may suggest new avenues for the treatment of pancreatic cancer - one of the deadliest human cancers. They may also offer a lesson that can be applied to the other cancer biomarkers that have not been ascribed roles in the etiology of disease. CA19-9, a glycan carbohydrate antigen present on many proteins, is commonly expressed at low levels within the pancreas. However, patients with pancreatic diseases, including cancer, often show increased levels of the antigen within their blood. As such, it has become one of the few biomarkers for these conditions, used for more than 30 years. Even so, how CA19-9 relates to disease pathogenesis is not well known. Because mice do not express CA19-9 on their own, a mouse model useful in studying this relationship has remained elusive. Danielle Engle and colleagues developed transgenic mouse models capable of reproducing the CA19-9 levels observed in human pancreatic cancer patients and, to their surprise, found that expression of CA19-9 in these mice resulted in severe pancreatitis and hyperactivation of epidermal growth factor receptor signaling, a known driver of pancreatic cancer. While CA19-9-mediated pancreatitis could be reversed using CA19-9 antibodies, the authors also found that CA19-9-expressing transgenic mice who also harbored an oncogene developed pancreatic cancer. "By understanding whether and how CA19-9 contributes to disease, we are now poised to apply this knowledge to improve the utility of CA19-9 both as a biomarker, but also as a new treatment strategy," said Engle. In a related Perspective, Christopher Halbrook and Howard Crawford discuss the study and its implications in more detail.
-end-


American Association for the Advancement of Science

Related Pancreatic Cancer Articles:

Bringing the 'sticky' back to pancreatic cancer
A multidisciplinary team of researchers at Japan's Tohoku University has found that a gene regulator, called BACH1, facilitates the spread of pancreatic cancer to other parts of the body.
Does lung damage speed pancreatic cancer?
High levels of CO2 in the body, due to chronic respiratory disorders, may exacerbate pancreatic cancer, making it more aggressive and resistant to therapy.
Scientists have identified the presence of cancer-suppressing cells in pancreatic cancer
Researchers have identified cells containing a protein called Meflin that has a role in restraining the progression of pancreatic cancer.
Pancreatic cancer discovery reveals how the aggressive cancer fuels its growth
A new discovery about pancreatic cancer sheds light on how the cancer fuels its growth and may help explain how promising cancer drugs work -- and for whom they will fail.
Overcoming resistance in pancreatic cancer
In pancreatic cancer cells' struggle to survive, the cells choose alternative routes when their main pathways are blocked by drugs.
Exposing how pancreatic cancer does its dirty work
Pancreatic cancer is a puzzle -- tumors slough off cells into the bloodstream early in the disease, but the tumors themselves have almost no blood vessels in them.
Targeting cell division in pancreatic cancer
Study provides new evidence of synergistic effects of drugs that inhibit cell division and support for further clinical trials.
Key to targeting the spread of pancreatic cancer
Targeting the tissue around pancreatic cancer cells may be the key to stopping their spread and improving chemotherapy outcomes.
Reprogramming pancreatic cancer
A type of white blood cell that has been especially susceptible to being deceived by pancreatic cancer cells into not attacking them can be 're-programmed' via a specially designed molecule that activates a protein found on their surfaces.
Pancreatic cancer collective comments on promising new pancreatic cancer
Lustgarten Foundation and SU2C offer comments on research describing a new combination drug therapy demonstrating promise for patients with pancreatic cancer.
More Pancreatic Cancer News and Pancreatic Cancer Current Events

Trending Science News

Current Coronavirus (COVID-19) News

Top Science Podcasts

We have hand picked the top science podcasts of 2020.
Now Playing: TED Radio Hour

Listen Again: Reinvention
Change is hard, but it's also an opportunity to discover and reimagine what you thought you knew. From our economy, to music, to even ourselves–this hour TED speakers explore the power of reinvention. Guests include OK Go lead singer Damian Kulash Jr., former college gymnastics coach Valorie Kondos Field, Stockton Mayor Michael Tubbs, and entrepreneur Nick Hanauer.
Now Playing: Science for the People

#562 Superbug to Bedside
By now we're all good and scared about antibiotic resistance, one of the many things coming to get us all. But there's good news, sort of. News antibiotics are coming out! How do they get tested? What does that kind of a trial look like and how does it happen? Host Bethany Brookeshire talks with Matt McCarthy, author of "Superbugs: The Race to Stop an Epidemic", about the ins and outs of testing a new antibiotic in the hospital.
Now Playing: Radiolab

Dispatch 6: Strange Times
Covid has disrupted the most basic routines of our days and nights. But in the middle of a conversation about how to fight the virus, we find a place impervious to the stalled plans and frenetic demands of the outside world. It's a very different kind of front line, where urgent work means moving slow, and time is marked out in tiny pre-planned steps. Then, on a walk through the woods, we consider how the tempo of our lives affects our minds and discover how the beats of biology shape our bodies. This episode was produced with help from Molly Webster and Tracie Hunte. Support Radiolab today at Radiolab.org/donate.